Physician profile
Michelle A Mitchell
NPI 1679779730
$2,722.49
in general payments reported to CMS, 2019-2025
26 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $798 · 2021: $938 · 2022: $20.69 · 2023: $12.92 · 2024: $44.24 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $370.40 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $351.38 | 2019-2021 | |
| Amgen INC. | $208.09 | 2019-2021 | |
| Lilly USA, LLC | $204.65 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.92 | 2019-2021 | |
| Abbvie INC. | $172.25 | 2021-2022 | |
| Amarin Pharma, INC. | $161.94 | 2019-2021 | |
| Pfizer INC. | $147.13 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $145.05 | 2019-2021 | |
| Insulet Corporation | $131.33 | 2019-2025 | Omnipod |
| Allergan, INC. | $76.52 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $75.05 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $69.88 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $62.14 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.46 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $51.62 | 2025 | |
| Lundbeck LLC | $45.65 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $35.71 | 2019-2020 | |
| Viatris Specialty LLC | $33.38 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $24.76 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.87 | 2019 | |
| Eisai INC. | $20.01 | 2021 | |
| Horizon Therapeutics Plc | $17.01 | 2021 | |
| Corcept Therapeutics | $16.54 | 2024 | Korlym |
| Axsome Therapeutics, INC. | $16.15 | 2025 | Auvelity |
| Currax Pharmaceuticals LLC | $13.60 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.